Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome.

Journal of clinical immunology - 1 Apr 2021

Alen Coutinho Iolanda, Regateiro Frederico S, Loureiro Carlos, Todo-Bom Ana

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Disease Management
Share to Hypereosinophilic Syndrome
Share to Receptor, Platelet-Derived Growth Factor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Severity of Illness Index

Share to Symptom Assessment

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 33394318
DOI: 10.1007/s10875-020-00946-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome.PMID 33394318Read ↗

Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.Semantic proximity Read ↗

[Genetic mutations and molecularly-targeted drugs in hypereosinophilic syndromes].Semantic proximity Read ↗

Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophiliaSemantic proximity Read ↗

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Semantic proximity Read ↗

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Semantic proximity Read ↗

Refractory/relapse thrombocytopenia in a patient with Evans’ syndrome successfully treated with zanubrutinibSemantic proximity Read ↗

Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids.Semantic proximity Read ↗

High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndromeSemantic proximity Read ↗

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.Semantic proximity Read ↗

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopeniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.